Inventor
ORONSKY BRYAN T
US27 patents
⚠️ This page may combine multiple inventors who share the name “ORONSKY BRYAN T”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
EPICENTRX INC
22 patentsUS9987270B1Jun 5, 2018
Treatment of gliomas using organonitro compound combination therapy
EPICENTRX INC16 citations92
US11008287B2May 18, 2021
Sulfoxyalkyl organonitro and related compounds and pharmaceutical compounds for use in medicine
EPICENTRX INC9 citations85
US10543208B2Jan 28, 2020
Treatment of gliomas using organonitro compound combination therapy
EPICENTRX INC12 citations85
US11160784B1Nov 2, 2021
Treatment of brain metastases using organonitro compound combination therapy
EPICENTRX INC8 citations83
US10342778B1Jul 9, 2019
Treatment of brain metastases using organonitro compound combination therapy
EPICENTRX INC13 citations83
US9468625B2Oct 18, 2016
Organonitro thioether compounds and medical uses thereof
EPICENTRX INC15 citations83
US11510901B2Nov 29, 2022
Methods and compositions utilizing RRx-001 combination therapy for radioprotection
EPICENTRX INC7 citations81
US11744859B2Sep 5, 2023
Compositions and methods for parenteral administration of therapeutic agents
EPICENTRX INC2 citations73
US11701351B2Jul 18, 2023
Treatment of gliomas using organonitro compound combination therapy
EPICENTRX INC2 citations72
US11576895B2Feb 14, 2023
Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
EPICENTRX INC4 citations72
US10906957B2Feb 2, 2021
Immunomodulatory fusion proteins
EPICENTRX INC2 citations72
US12109348B2Oct 8, 2024
Medication infusion devices, systems, and methods
EPICENTRX INC2 citations69
US12048793B2Jul 30, 2024
Medication infusion devices, systems, and methods
EPICENTRX INC2 citations66
US11660286B2May 30, 2023
Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
EPICENTRX INC3 citations65
US12295976B2May 13, 2025
Personalized cancer vaccines
EPICENTRX INC0 citations62
US12291726B2May 6, 2025
A549 host cells comprising a recombinant oncolytic adenovirus with modified E1A cancer-specific promoter
EPICENTRX INC0 citations62
US12054530B2Aug 6, 2024
Immunomodulatory fusion proteins
EPICENTRX INC0 citations62
US12036247B2Jul 16, 2024
Multiple transgene recombinant adenovirus
EPICENTRX INC0 citations62
US11999973B2Jun 4, 2024
Method for producing recombinant oncolytic adenovirus with modified E1a cancer-specific promoter
EPICENTRX INC0 citations62
US11834492B2Dec 5, 2023
Human IL-10 receptor alpha fusion proteins
EPICENTRX INC1 citations62
US12357607B2Jul 15, 2025
Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
EPICENTRX INC0 citations59
US12357608B2Jul 15, 2025
Methods and compositions utilizing RRx-001 combination therapy for radioprotection
EPICENTRX INC0 citations58